Prescription Medicines
Duorovan Tab. 10/10 mg
- Product Category
- Hypercholesterolemia treatment
- Active Ingredients
- Ezetimibe, rosuvastatin calcium
- Appearance
- A white to almost white, round, film-coated tablet.
- Reimbursement Code
- 648103750
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Ezetimibe (micronized) (in-house specification) ---------- 10mg
Rosuvastatin Calcium (EP) ---------- 10.4mg (10mg as rosuvastatin)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Microcrystalline cellulose, butyl hydroxyanisole, magnesium stearate, Opadry white (03B28796), carnauba lead, croscarmellose sodium, hydroxypropyl cellulose
2. Efficacy/Effectiveness
Primary hypercholesterolemia
This drug is administered as an adjunct to diet to reduce elevated total cholesterol (total-C), LDL-C, apo B protein (Apo B), triglyceride (TG), and non-HDL-cholesterol and to increase HDL-cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia.
Many risk factors must be considered when administering lipid-modifying drugs to patients at increased risk of arteriosclerotic vascular disease due to hypercholesterolemia. Lipid-modifying drugs should be used in conjunction with appropriate diet (including restriction of saturated fat and cholesterol) and when response to diet and other non-pharmacological measures is inadequate.
Prior to administering this drug, other secondary causes of dyslipidemia (e.g., diabetes, hypothyroidism, obstructive liver disease, chronic renal failure, drugs that increase LDL-cholesterol and drugs that reduce HDL-cholesterol [progestin, anabolic steroid, and corticosteroid]) should be identified, and secondary causes should be treated if necessary.
Lipid testing should include total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides. If the triglyceride level is more than 400 mg/dL (more than 4.5 mmol/L), the LDL-cholesterol concentration must be measured by ultracentrifugation. If you are hospitalized for an acute coronary accident, lipids should be measured upon admission or within 24 hours after admission. This measurement can be used as a reference in starting LDL-lowering treatment before or upon discharge of the patient.
3. Usage/Dosage
This drug is administered once daily, regardless of meal.
Patients before or while taking this drug must continue to follow a standard cholesterol-lowering diet. The dosage of this drug should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goals, and patient response.
Primary hypercholesterolemia
The dosage range of this drug is 10/5mg to 10/20mg per day. The recommended initial dose is 10/5 mg per day. For patients who require greater LDL-cholesterol reduction, the dose can be adjusted. After starting this drug or titrating the dose, check the blood lipid level at intervals of 4 weeks or more and adjust the dose accordingly. The dose can be increased up to 10/20 mg per day.
If a patient is taking ezetimibe and rosuvastatin in combination, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.
4. Precautions for use
1. Warning
Rhabdomyolysis accompanied by acute renal failure secondary to myoglobinuria has been rarely reported with rosuvastatin and other drugs in the same class. Therefore, treatment with this drug should be temporarily withheld or discontinued in patients presenting with acute, severe myopathy or with risk factors that may cause renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, uncontrolled seizures) (see ‘5. General Precautions’).
2. Do not administer to the following patients
1) Patients with hypersensitivity to the main ingredient or components of this drug
2) Patients with active liver disease or patients with persistently high serum transaminase levels for unknown reasons (see ‘5. General precautions’)
3) Patients with muscle disease
4) Patients taking cyclosporine concurrently
5) Patients with severe renal failure (creatinine clearance (CLcr) <30mL/min)
6) Pregnant women, women who may be pregnant, and lactating women (see ‘7. Administration to pregnant and lactating women’)
7) Rosuvastatin at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
(1) Moderate renal impairment (creatinine clearance <60ml/min)
(2) Hypothyroidism
(3) If you have a history or family history of genetic muscle disease
(4) If there is a history of muscle toxicity from other statin drugs (HMG-CoA converting enzyme inhibitors) or fibrate drugs
(5) alcoholism
(6) Situations in which plasma concentrations may increase
(7) Asian patients
(8) Concurrent administration of fibrate-based drugs
8) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer with caution to the following patients:
1) Patients with a history of alcoholism or liver disease
2) Patients with moderate or severe liver function impairment: In patients with moderate or severe liver function impairment, administration of this drug is not recommended as the systemic exposure to rosuvastatin and ezetimibe may increase and unexpected effects may occur.
3) Patients with factors predisposing to myopathy/rhabdomyolysis, such as:
(1) History of impaired renal function or renal failure
(2) Hypothyroidism
(3) History or family history of genetic muscle disease
(4) History of muscle toxicity to statin drugs or fibrate drugs
(5) If you have a history of liver disease or consume a significant amount of alcohol
(6) Elderly over 70 years old with factors causing rhabdomyolysis
(7) Cases where blood drug concentration may increase
4) Patients taking concomitant fibrate drugs
5) Patients with severe muscle atony or ocular muscle atony (cases of recurrence when administered the same or different types of statin drugs have been reported).
6) Acute severe conditions suggestive of worsening myopathy or renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte disorders, uncontrolled epileptic seizures)
4. Adverse reactions
○ Information collected from ezetimibe/rosuvastatin combination drug
1) The safety of this drug was evaluated in a rosuvastatin-controlled clinical trial targeting 369 patients with primary high cholesterol. This clinical trial consists of an 8-week treatment period and a 12-week extension period. The 12-week extension period was conducted on 258 patients who completed the 8-week treatment period and whose LDL-C levels reached the treatment target according to their risk for cardiovascular disease.
(1) Adverse reactions collected during the 8-week treatment period
The most commonly reported adverse reactions during this period were nasopharyngitis (2.4%), arthralgia (1.4%), and headache (1.4%). Adverse reactions related to this drug were 2 cases of ALT elevation, 2 cases of AST elevation, 2 cases of muscle pain, 1 case of edema, 1 case of increase in blood bilirubin, 1 case of acneiform dermatitis, and 1 case of pruritus, all of which were mild or moderate.
<Table 1> Adverse reactions reported in more than 1% of patients during the 8-week treatment period
* Please refer to the attached manual for detailed information. *
(2) Adverse reactions collected during the 12-week extension period
The most commonly reported adverse reactions during this period were nasopharyngitis (5.04%), increased ALT (2.71%), increased AST (1.94%), dizziness (1.94%), upper respiratory tract infection (1.55%), and muscle pain (1.16%). All other adverse reaction incidence rates were less than 1%. As with the 8-week controlled clinical trial of rosuvastatin, no adverse reactions specific to this drug were observed.
2) Domestic post-marketing surveillance results following re-examination
For reexamination in Korea, six post-marketing surveys of ezetimibe/rosuvastatin combination drugs were conducted on a total of 10,317 people over a period of six years. Regardless of causal relationship, the occurrence rate of adverse events was 11.11% (71/639 people, 101 cases), 11.61% (529/4556 people, 790 cases), 15.85% (100/631 people, 156 cases), 11.73% (306/2,608 people, 412 cases), respectively, for each post-marketing surveillance. It was reported as 6.76% (85/1,258 people, 117 cases) and 6.88% (43/625 people, 59 cases). Among these, serious adverse drug reactions for which a causal relationship cannot be ruled out and unexpected adverse drug reactions for which a causal relationship cannot be ruled out were reported as shown in the table below.
* Table_Please refer to the attached manual for detailed information. *
* The number of serious adverse drug reactions and unexpected adverse drug reactions listed in the table above is a compilation of individual post-marketing surveillance results.
The information specified below is based on clinical trials and post-marketing experience with the individual ingredients rosuvastatin and ezetimibe.
○ Information collected from rosuvastatin
1) Reported adverse reactions were generally mild and transient. Less than 4% of patients in the rosuvastatin treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows:
Common (>1/100, <1/10);
Uncommon (>1/1,000, <1/100);
Rare (>1/10,000, <1/1,000);
Very rare (<1/10,000).
Not known (cannot be estimated from available data)
<Table 2> Adverse reactions occurring during rosuvastatin administration
* Please refer to the attached manual for detailed information. *
As with other statin drugs, adverse reactions tended to increase as the dose increased.
2) Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered rosuvastatin, but the frequency of occurrence was low.
3) Effects on the musculoskeletal system: Effects on the musculoskeletal system with or without acute renal failure (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) have been reported in patients treated with all doses of rosuvastatin (especially doses above 20 mg). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
4) Effects on the liver: As with other statin drugs, transaminase levels increased in a dose-dependent manner in a small number of patients receiving rosuvastatin. In most cases, it was mild, asymptomatic, and transient.
5) Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with increased eosinophils and systemic symptoms (DRESS) (frequency unknown)
- Musculoskeletal system: very rare, arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
Post-marketing cognitive impairment has been rarely reported in association with statin drug use. (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks). The induction or worsening of severe muscle atony or ocular muscle atony has been reported with the administration of statin drugs.
6) Domestic post-marketing survey results
As a result of a use result survey conducted on 3,081 people over 6 years for re-examination in Korea, the incidence of adverse events regardless of causal relationship was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) respectively. Of these, 2.92% (90 people, 106 cases) of adverse drug reactions for which a causal relationship with rosuvastatin could not be ruled out.
The most reported adverse drug reactions were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not occur before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% each (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% each (2 patients, 2 cases), syncope, and Systemic pain, muscle spasms, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased blood creatinine were reported as serious and unexpected adverse drug reactions.
7) Pediatric patients aged 10 to 17 years
In a 52-week clinical trial conducted on pediatric patients aged 10 to 17 years, elevated creatinine kinase levels exceeding 10 times the upper limit of normal range (10 x ULN) after exercise and increased physical activity were observed more frequently than in adult patients. In other respects, the safety profile of pediatric patients was similar to that of adults.
○ Information collected from ezetimibe
The safety of ezetimibe was evaluated in more than 4,700 patients in clinical trials. As a result of clinical trials on ezetimibe (administered alone or in combination with an HMG-CoA reductase inhibitor), ezetimibe was generally well tolerated. The total incidence of adverse reactions reported with ezetimibe was similar to the incidence of adverse reactions reported with placebo, and the rate of discontinuation of medication due to adverse reactions was also similar to that of placebo.
1) Single administration
In placebo-controlled clinical trials, adverse reactions were reported in more than 2% of patients administered ezetimibe, regardless of causality assessment, and adverse reactions reported at a higher rate than the incidence in the placebo group are shown in <Table 3>.
<Table 3*> Clinical adverse reactions reported in more than 2% of patients treated with ezetimibe, regardless of causality assessment, and reported at a higher rate than the rate in the placebo group
* Please refer to the attached manual for detailed information. *
The occurrence rates of other adverse reactions that occurred at a lower frequency than the above adverse reactions were similar between the ezetimibe group and the placebo group (see Table 4).
2) Concurrent administration with HMG-CoA reductase inhibitor
The safety of ezetimibe was evaluated in more than 2,000 patients in a combination clinical trial.
Adverse reactions when ezetimibe and HMG-CoA reductase inhibitors were administered together were generally similar to those when HMG-CoA reductase inhibitors were administered alone. However, compared to patients receiving HMG-CoA reductase inhibitors alone, patients receiving ezetimibe and HMG-CoA reductase inhibitors together had a slightly higher incidence of elevated aminotransferase levels.
In four placebo-controlled clinical trials in which ezetimibe was administered alone or simultaneously with various HMG-CoA reductase inhibitors, adverse reactions that were reported in more than 2% of cases regardless of causality assessment and that were reported at a higher rate than the placebo group are shown in <Table 4>.
<Table 4*> Clinical adverse reactions reported in more than 2% of patients regardless of causality assessment in clinical trials of ezetimibe/statin combination administration and at a higher rate than the placebo group
* Please refer to the attached manual for detailed information. *
3) Concurrent administration with fenofibrate
A multicenter, double-blind, placebo-controlled clinical trial was conducted on 625 patients with mixed dyslipidemia for up to 12 weeks and 576 patients with mixed dyslipidemia for up to 1 year. This study was not designed to compare rare adverse reactions between treatment groups. The incidence (95% CI) of clinically important elevations (more than 3 times the upper limit of normal, persistent) of serum transaminases was 4.5% (1.9, 8.8) in the fenofibrate monotherapy group and 2.7% (1.2, 5.4) in the ezetimibe and fenofibrate combination group, when adjusting for dose exposure. The incidence of cholecystectomy was 0.6% (0.0, 3.1) in the fenofibrate-only group and 1.7% (0.6, 4.0) in the ezetimibe and fenofibrate combination group. In each administration group of this test, there was no case where creatine phosphokinase (CPK) increased more than 10 times the upper limit of normal.
4) Commonly reported adverse reactions related to the drug in the ezetimibe alone group (n=1691), the ezetimibe and statin drug combination group (n=1675), or the ezetimibe and fenofibrate combination treatment group (n=185) are as follows (≥1/100, <1/10).
․Ezetimibe single-administration group: Headache, abdominal pain, diarrhea
․Ezetimibe and statin drug combination group: headache, fatigue, abdominal pain, constipation, diarrhea, flatulence, nausea, increased AST, increased ALT, muscle pain.
․Ezetimibe and fenofibrate combination group: abdominal pain
5) Post-marketing adverse reactions
The following adverse reactions were reported post-marketing regardless of causality assessment.
Hypersensitivity reactions including anaphylaxis, urticaria, rash and angioedema, erythema multiforme, arthralgia, myalgia, increased creatine phosphokinase level, myopathy/rhabdomyolysis (see section ‘5. General precautions’), increased liver aminotransferase level, hepatitis, abdominal pain, thrombocytopenia, nausea, pancreatitis, dizziness, paresthesia, depression, headache, cholelithiasis, cholecystitis.
6) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,536 patients over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 7.27% (257/3,536, 422 cases) regardless of causal relationship. The most common adverse event (more than 1.0%) was fatigue at 1.05% (37 people/3,536 people, 37 cases). The adverse drug reaction rate, which is an adverse event in which a causal relationship with ezetimibe cannot be ruled out, was 1.95% (69 people/3,536 people, 108 cases). Increased ALT and AST were the most common at 0.28% (10 people/3,536 people, 10 cases), followed by diarrhea at 0.17% (6 people/3,536 people, 6 cases), indigestion and dizziness at 0.14% (5 people/3,536 people, 5 cases) each, and nausea at 0.11% (4 people/3,536 people, 5 cases). 4 cases), and other adverse drug reactions reported in less than 0.1% are classified by institution as follows.
- Whole body: fatigue, chest pain, chest discomfort, edema, asthenia, generalized edema
- Nervous system: headache, diabetic neuropathy, tremor
- Digestive system: epigastric pain, vomiting, abdominal pain, gastritis, constipation, dry mouth, solar plexus discomfort, belching, gastrointestinal disorders, gastroesophageal reflux disease, tongue disease
- Cardiovascular system: palpitations, congestive heart failure, myocardial ischemia, flushing
- Respiratory system: cough, phlegm, runny nose
- Musculoskeletal system: limb pain, joint pain
- Metabolism and nutrition: diabetes, hypoglycemia
- Blood system: anemia, splenomegaly
- Skin: hives, hyperhidrosis, rash, itching
- Infection: Upper respiratory infection
- Eyes: Conjunctival redness
- Urinary system: renal failure (kidney disease)
- Hepatobiliary system: liver dysfunction
- Clinical tests: increased blood creatinine, increased blood pressure, increased blood urea, increased CPK, abnormal liver function test
5. General precautions
1) Myopathy/Rhabdomyolysis
For patients with factors predisposing to myopathy/rhabdomyolysis (see section ‘3. Administer with caution to the following patients’), CPK levels should be measured before starting administration and administered with caution. In these patients, the risks of treatment should be considered along with the benefits, and clinical monitoring is recommended.
CPK is not measured after strenuous exercise or when there are other potential factors that may cause CPK elevation, as it is difficult to interpret CPK levels. If the CPK level significantly increases from baseline to more than 5 times the upper limit of normal, it should be measured again after 5 to 7 days to confirm the result.
If CPK levels are significantly increased beyond 5 times the upper limit of normal from baseline after 5 to 7 days, treatment with this drug should not be initiated.
When starting treatment with this drug, patients should be informed of the risk of myopathy, and if muscle pain, cramps, or muscle weakness accompanied by malaise or fever occur while taking this drug, patients should be instructed to immediately report this to their doctor. Additionally, if these symptoms occur, CPK levels should be measured, and if CPK levels increase significantly (more than 5 times the upper limit of normal), administration of this drug should be discontinued. Even if the CPK level is less than 5 times the upper limit of normal, the drug should be discontinued if muscle symptoms are severe and cause daily discomfort. If symptoms improve and CPK levels return to normal and this drug is re-administered or other statin-containing preparations are administered, administer at the lowest dose while closely monitoring the patient.
○ Rosuvastatin
As with other statins, effects on skeletal muscle, such as myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving rosuvastatin. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statin drugs, including rosuvastatin. Immune-mediated myopathy is clinically characterized by proximal muscle weakness and increased CPK in the blood, and the symptoms persist even after discontinuation of administration.
In clinical trials, there was no evidence of increased effects on skeletal muscle in the small number of patients receiving rosuvastatin in combination with other drugs. However, in the case of other statin drugs, the frequency of myositis and myopathy increased in patients who were also receiving fibric acid derivatives (including gemfibrozil), cyclosporin, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when combined with statin drugs. Therefore, combined use of rosuvastatin and gemfibrozil is not recommended. When rosuvastatin is coadministered with fibrates or niacin, the benefits and risks must be carefully evaluated. A dose of 40 milligrams of rosuvastatin is contraindicated when coadministered with fibrate-based drugs.
○ Ezetimibe
The risk of musculoskeletal toxicity increases when there are factors such as concurrent use with high-dose statin drugs, elderly patients (over 65 years of age), hypothyroidism, renal impairment, type of statin drug administered, and concurrent use with other drugs.
Myopathy and rhabdomyolysis have been reported with ezetimibe after marketing. Most patients who developed rhabdomyolysis were taking statins before receiving ezetimibe. However, rhabdomyolysis has been reported when ezetimibe is administered alone, and rhabdomyolysis has also been reported when ezetimibe is coadministered with drugs that increase the risk of rhabdomyolysis, such as fibric acid derivatives.
If myopathy is diagnosed or suspected when coadministering ezetimibe and fenofibrate, administration of ezetimibe and fenofibrate should be discontinued immediately. Cases where CPK levels rise to more than 10 times the upper limit of normal along with muscle symptoms can be considered myopathy.
2) Liver enzymes
Liver enzyme tests should be performed before starting treatment with this drug, and liver function tests should be repeated in patients who demonstrate clinical signs or symptoms of liver damage. Patients with elevated transaminases should be monitored until symptoms improve. If transaminases continue to increase more than 3 times the upper normal limit, it is recommended to reduce the dose or discontinue the drug.
In post-marketing studies in patients taking statins, including rosuvastatin, rare cases of fatal and non-fatal liver failure have been reported.
If severe liver damage and/or hyperbilirubinemia or jaundice occurs along with clinical symptoms during treatment with this drug, treatment with this drug should be discontinued immediately. If no other etiology is identified, do not re-administer this drug.
Caution should be exercised when administering this drug to patients who have overdosed on alcohol and/or have a history of liver disease. This drug should not be administered to patients with active liver disease or persistent elevations in serum transaminases of unknown cause. (Refer to ‘2. Do not administer to the following patients’)
○ Ezetimibe
In controlled clinical trials, the incidence of persistent elevations in liver aminotransferase levels (more than three times the upper limit of normal) was similar in the ezetimibe group (0.5%) and the placebo group (0.3%).
In a controlled clinical trial on the combined administration of ezetimibe and statins, the incidence of consecutive elevations in liver aminotransferase levels (more than three times the upper limit of normal) was 0.6% in the group administered with ezetimibe and statins. These aminotransferase elevations generally did not cause symptoms, were not related to cholestasis, and returned to baseline levels after discontinuation or continued administration.
3) Endocrine system function
Increases in HbA1c and fasting blood sugar levels have been reported in patients taking statins, including rosuvastatin. However, the benefit of reducing vascular risk from statin administration outweighs the risk of hyperglycemia.
4) Interstitial lung disease
Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Symptoms that develop may include difficulty breathing, non-productive cough and general deterioration of health (fatigue, weight loss and fever). If a patient is suspected of having interstitial lung disease, treatment with statin drugs should be discontinued.
5) Diabetes
There is some evidence that statins may cause hyperglycemia, which may require appropriate diabetes treatment in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statin drugs exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar level 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo both clinical and laboratory monitoring according to treatment guidelines.
6) Concurrent administration with other drugs
(1) Anticoagulants: When adding this drug to patients taking warfarin, other coumarin anticoagulants, or fluinedione, the INR must be appropriately monitored. Additionally, when administering this drug to a patient taking a coumarin-based anticoagulant, the prothrombin time should be measured before administration and should be measured frequently enough in the early stages of treatment to confirm that the prothrombin time does not change significantly. Once a stable prothrombin time is established, it can be monitored periodically. If the dose of this drug is changed or treatment is discontinued, the same process as above must be repeated.
(2) Fibrate-based drugs: Fibrate-based drugs can cause cholelithiasis by increasing cholesterol excretion into bile. If cholelithiasis is suspected in patients taking this drug and fibrates in combination, gallbladder investigation should be performed and alternative lipid-lowering therapy should be considered.
(3) Bile acid binding resin: This drug should be administered 2 hours before or 4 hours after administration of bile acid binding resin.
(4) Fusidic acid: In post-marketing experience, muscle-related adverse reactions, including rhabdomyolysis, were reported when rosuvastatin and fusidic acid were used together, so the combined use of rosuvastatin and fusidic acid is not recommended.
(5) Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP. Caution should be exercised when using this drug together with an inhibitor of this transporter protein, as the blood concentration of this drug may increase, increasing the risk of myopathy (see section 6. Interactions).
7) Genetic polymorphism: SLCO1B1(OATP1B1) c compared to SLCO1B1 c.521TT and ABCG2 c.421CC. The genotype of 521CC or ABCG2 (BCRP) c.421AA has been reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of this drug according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
8) Women of childbearing potential
Women of childbearing potential should use appropriate contraception while taking this drug.
9) Effects on driving and operating machines: There have been no studies on the effects on driving and operating machines, but it should be considered that dizziness may occur in patients taking this drug.
10) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS), eosinophilia, and drug reaction syndrome with systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be counseled and closely monitored for symptoms and signs of severe skin reactions. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
11) Severe muscle asthenia and ocular muscle atony: Rarely, statin drugs may cause or worsen severe muscle asthenia or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.
6. Interaction
No clinically significant pharmacokinetic interactions were observed when co-administered with rosuvastatin, the main ingredient of this drug, and ezetimibe.
Studies on drug interactions between other drugs and rosuvastatin/ezetimibe combination drugs have not been conducted, but studies on individual drugs rosuvastatin and ezetimibe have been conducted as follows.
○ Rosuvastatin
1) How other drugs affect rosuvastatin
In vitro and in vivo studies have shown that rosuvastatin does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP, and when inhibitors of these transporter proteins are used together with rosuvastatin, the blood concentration of rosuvastatin increases, which may increase the risk of myopathy (see Table 5 below).
Table 5: Effect of other drugs on rosuvastatin exposure (AUC) (based on published clinical results)
* Please refer to the attached manual for detailed information. *
Effects of other drugs
(1) Antacid: When rosuvastatin was co-administered with an antacid containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by about 50%. However, this effect was alleviated when antacids were administered 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.
(2) Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
(3) Ticagrelor: Ticagrelor may affect the excretion of rosuvastatin through the kidneys, increasing the risk of rosuvastatin accumulation. In some cases, coadministration of ticagrelor and rosuvastatin resulted in decreased renal function, increased CPK levels, and rhabdomyolysis.
2) Effect of rosuvastatin on other drugs
(1) Warfarin: When used in combination with rosuvastatin, warfarin has no significant effect on pharmacokinetics. However, like other statin drugs, coadministration of rosuvastatin and warfarin may increase the INR compared to administration of warfarin alone. INR monitoring is recommended when starting, stopping, or adjusting the dose of rosuvastatin in patients receiving vitamin K antagonists (e.g., warfarin).
(2) Cyclosporine: Co-administration of rosuvastatin and cyclosporine does not affect the blood concentration of cyclosporine.
(3) Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, so the risk of myopathy increases when administered in combination with statin drugs. When co-administering fibrate-type drugs, administration of 40 mg of rosuvastatin is contraindicated, and 5 mg should be administered as the initial dose.
(4) Oral contraceptives: When administered together with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data for patients taking rosuvastatin and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
(5) Effect on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
○ Ezetimibe
1) Cholestyramine: When ezetimibe and cholestyramine were administered together, the average AUC of total ezetimibe decreased by about 55%. Due to this interaction, the combined effect on lowering LDL-C expected from the combined administration of cholestyramine and ezetimibe may be reduced.
2) Fibrate-based drugs: In clinical trials, the safety and effectiveness of combined administration of ezetimibe and fenofibrate were evaluated. Coadministration of ezetimibe with other fibrates has not been studied. Fibrates can cause gallstones by increasing cholesterol excretion into bile. Ezetimibe increased gallbladder bile cholesterol in preclinical studies in dogs. Although the relevance of these preclinical findings to humans is unknown, coadministration of ezetimibe and fibrates (except fenofibrate) is not recommended until the results of studies in patients are available.
(1) Gemfibrozil: In a pharmacokinetic study, the total ezetimibe concentration increased by about 1.7 times with the combined administration of ezetimibe and gemfibrozil, but this was not clinically significant. There is no relevant clinical data yet.
(2) Fenofibrate: If cholelithiasis is suspected in a patient taking ezetimibe and fenofibrate together, the gallbladder should be examined and other lipid-lowering treatment should be considered. In a pharmacokinetic test, combined administration of ezetimibe and fenofibrate increased the total ezetimibe concentration by approximately 1.5 times, but this was not clinically significant.
3) Statin drugs: No clinically significant pharmacokinetic interactions were observed when coadministering ezetimibe with atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, and rosuvastatin.
4) Cyclosporine: Caution should be exercised when co-administering ezetimibe to patients taking cyclosporine. If ezetimibe and cyclosporine are coadministered, the concentration of cyclosporine should be monitored. When ezetimibe was co-administered with a stable dose of cyclosporine (75-150 mg twice daily) to eight kidney transplant patients with mild renal impairment or normal renal function (creatinine clearance > 50 mL/min), the average AUC and C max of total ezetimibe were 3.4 times each (range) compared to healthy historical controls (n=17). It increased to 2.3 to 7.9 times) and 3.9 times (range 3.0 to 4.4 times). In another clinical study, when several drugs, including cyclosporine, were administered to one patient with severe renal impairment (creatinine clearance = 13.2 mL/min/1.73 m2) who had received a kidney transplant, the total ezetimibe exposure increased 12-fold. In a two-period crossover study in 12 healthy volunteers, when ezetimibe 20 mg once daily for 8 days and cyclosporine 100 mg as a single dose on day 7 were administered as a single dose, the AUC of cyclosporine increased by an average of 15% compared to the control group when cyclosporine 100 mg was administered alone (range 10% decrease to 51% increase).
5) Anticoagulants: When coadministering ezetimibe with warfarin, other coumarin anticoagulants, or fluinedione, the prothrombin time (International Normalized Ratio, INR) must be appropriately monitored. In a clinical study involving 12 healthy adult men, there was no significant effect on the bioavailability and prothrombin time of warfarin due to the co-administration of warfarin and ezetimibe (10 mg per day). However, after marketing, it was reported that INR increased in patients who received ezetimibe in combination with warfarin or fluindione. Most of these patients were also taking other medications.
7. Administration to pregnant and lactating women
1) Arteriosclerosis is a chronic disease, and discontinuation of lipid-lowering medication during pregnancy does not affect the long-term treatment results of primary hypercholesterolemia. Additionally, cholesterol and other products of the cholesterol biosynthetic pathway are essential components for fetal development, such as steroids and cell membrane synthesis.
HMG-CoA reductase inhibitors, including rosuvastatin, may reduce cholesterol synthesis and other products of the cholesterol biosynthetic pathway, so this drug should not be administered to pregnant or lactating women.
Since the safety of this drug in pregnant women has not been established, administration should be discontinued immediately if pregnancy is confirmed, and the patient should be informed of the potential risk to the fetus. For women of childbearing potential who have little chance of becoming pregnant, administer the drug only after being informed of the potential risk to the fetus and the lack of clinical benefit from continuing administration during pregnancy.
2) Since it has not been confirmed whether the components of this drug are secreted into breast milk, this drug should not be administered to nursing mothers unless the potential benefit of this drug outweighs the potential risk to the infant.
○ Rosuvastatin
The safety of rosuvastatin in pregnant and lactating women has not been established and should not be used during pregnancy or lactation.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using rosuvastatin, you should stop taking it immediately. Rosuvastatin is passed into rat breast milk. There are no data on transfer to breast milk in humans.
○Ezetimibe
1) There is no clinical data on the administration of ezetimibe to pregnant women. Ezetimibe should be used in pregnant women only when the potential benefits outweigh the potential risks to the infant.
2) No embryonic lethal effect was observed at the test doses (250, 500, 1000 mg/kg/day) in oral embryo/fetal development tests on rats and rabbits in the organogenesis period. In rats administered ezetimibe at 1000 mg/kg/day (10 times the human exposure at 10 mg/day based on the AUC0-24hr of total ezetimibe), an increased incidence of common fetal skeletal abnormalities (rib extraplasia, central cervical ossification, and rib shortening) was observed. Rib addition was observed in rabbits administered ezetimibe at 1000 mg/kg/day (150 times the human exposure at 10 mg/day based on AUC0-24hr of total ezetimibe). Ezetimibe crossed the placenta when repeatedly administered to pregnant rats and rabbits.
3) All HMG-CoA reductase inhibitors and fenofibrate are prohibited for administration to pregnant and lactating women. When administering ezetimibe together with an HMG-CoA reductase inhibitor or fenofibrate to women of childbearing potential, refer to the product instructions for the relevant HMG-CoA reductase inhibitor or fenofibrate.
4) In a repeated administration test in which ezetimibe and HMG-CoA reductase inhibitors (statin drugs) were co-administered to rats and rabbits in the organogenesis period, the degree of exposure to ezetimibe and HMG-CoA reductase inhibitors was high. Abnormalities in reproductive function were observed at lower doses during combined administration compared to single administration.
5) In animal experiments (rats), ezetimibe was secreted into milk. In experiments in rats, total ezetimibe exposure in lactating pups was half that observed in maternal plasma. It is not known whether ezetimibe is excreted in human breast milk. Therefore, ezetimibe should not be administered to nursing mothers unless the potential benefits of ezetimibe outweigh the potential risks to the infant.
8. Administration to children
This drug is not recommended for use in children because its safety and effectiveness have not been established.
○ Rosuvastatin
In pediatric patients aged 10 to 17 years taking rosuvastatin, evaluation of secondary sexual characteristics, linear growth (height), weight, and body mass index (BMI) by Tanner staging is limited to 1 year.
○ Ezetimibe
To evaluate the safety and effectiveness of ezetimibe, a clinical trial was conducted for 12 weeks on pediatric patients (6-10 years old) with heterozygous familial and non-familial hypercholesterolemia. The adverse reaction profile when ezetimibe was administered to pediatric patients and the adverse reaction profile when administered to adult patients were similar. This clinical trial found no effects on development or sexual maturation in children. However, there are no studies in which ezetimibe was administered to pediatric patients for more than 12 weeks.
9. Administration to elderly people
Old age (over 65 years old) is one of the factors that predisposes to myopathy, so caution should be exercised when administering this drug to elderly people. No dosage adjustment of this drug is necessary in elderly people.
10. Administration to patients with hepatic impairment
Do not administer this medicine to patients with active liver disease or unexplained, persistently elevated hepatic aminotransferase levels. See “2. Contraindications” and “5. General Precautions.”
11. Administration to patients with renal impairment
A history of renal impairment may be a risk factor for developing rhabdomyolysis. These patients may benefit from close monitoring of skeletal muscle effects (see ‘5. General precautions’).
○Ezetimibe
After administering ezetimibe 10mg once daily to patients with severe renal impairment (n=8, creatinine clearance ≤ 30ml/min/1.73㎡), the average AUC of total ezetimibe increased by about 1.5 times compared to healthy subjects (n=9). These results are not clinically significant, and no dose adjustment is necessary for patients with renal impairment.
12. Treatment in case of overdose
There is no specific treatment recommended for overdose of this drug. In case of overdose of this drug, symptomatic treatment and appropriate supportive care should be provided. Additionally, liver function tests and serum CPK levels should be monitored.
○ Ezetimibe
1) There have been several reports of overdose with ezetimibe. Most of them were not accompanied by adverse reactions, and the adverse reactions reported were not severe. In case of overdose, provide general symptomatic and supportive care.
2) In clinical trials, tolerability was generally excellent when 50 mg of ezetimibe per day was administered to 15 healthy subjects for up to 14 days, or when 40 mg of ezetimibe per day was administered to 18 patients with primary dyslipidemia for up to 56 days.
13. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
14. Information for experts
1) Pharmacological action
(1) Rosuvastatin is an HMG-CoA reductase inhibitor and inhibits the synthesis of mevalonate, a precursor of cholesterol.
(2) Ezetimibe selectively inhibits the intestinal absorption of cholesterol and phytosterols.
2) Pharmacokinetic information
(1) One biopharmaceutical study compared the bioavailability of this fixed-dose combination with that of the individual products taken together. In a 2 × 2 crossover study, 41 healthy adults received a single fasting dose of rosuvastatin 10 mg and ezetimibe 10 mg, either as the combination or as separate products (test: one 10/10 mg tablet of this product; reference: one Crestor 10 mg tablet and one Ezetrol tablet). Pharmacokinetic parameters were compared using plasma rosuvastatin and ezetimibe concentrations. The 90% confidence intervals for the differences in the means of the log-transformed AUCt and Cmax values were all within log 0.8 to log 1.25, meeting the bioequivalence criteria.
(2) One comparative pharmacokinetic study was conducted to evaluate the pharmacokinetic drug interaction between rosuvastatin and ezetimibe. A total of 56 healthy adults participated and took 20 mg of rosuvastatin and 10 mg of ezetimibe alone or in combination for 7 days (2 treatment groups, 2 × 2 crossover trial each). The 90% confidence interval of the log-transformed mean difference of AUCτ,ss and Cmax,ss during combined administration compared to single administration is 1.037 (0.977 ~ 1.101) and 1.037 (0.945 ~ 1.137) for rosuvastatin, respectively, and 1.211 (1.094 ~ 1.341) for free ezetimibe, respectively. and 1.130 (0.994 ~ 1.285), and the total ezetimibe including active metabolites were 1.130 (1.022 ~ 1.249) and 1.069 (0.976 ~ 1.171), respectively. No clinically significant pharmacokinetic interaction was observed when the two components were administered together.
(3) Although not a test conducted with this drug, rosuvastatin increased the median AUC and Cmax approximately two-fold in Asians (Japan, China, Philippines, Vietnam, Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
3) Clinical trial information
One multicenter, randomized, double-blind, parallel, factorial design trial was conducted with 369 patients (safety set) with primary hypercholesterolemia. This trial consisted of an 8-week treatment phase and a 12-week extension phase. In this trial, patients underwent therapeutic lifestyle correction for more than 4 weeks before randomization, and then a fasting lipid test was performed. Finally, eligible subjects were randomly assigned to the test group (10/20 mg, 10/10 mg, 10/5 mg of this drug) or the control group (20 mg, 10 mg, 5 mg of rosuvastatin).
After an 8-week treatment period, a superiority test was conducted at a significance level of 5% between the overall rosuvastatin/ezetimibe combination group compared to the overall rosuvastatin single agent group at all doses. As a result, the rosuvastatin/ezetimibe combination group showed a statistically superior LDL-C lowering effect compared to the rosuvastatin single agent group (p-value <0.0001).
As a result of sequentially testing the superiority of the rosuvastatin/ezetimibe combination group over the rosuvastatin single agent group at rosuvastatin doses of 5 mg, 10 mg, and 20 mg, the rosuvastatin/ezetimibe combination group showed a statistically superior LDL-C lowering effect compared to the rosuvastatin single agent group at all doses (p-value<0.0001).
* Please refer to the attached manual for detailed information. *
After completing the treatment period, only patients whose LDL-C level reached the treatment goal according to NCEP ATP III took this drug for an additional 12 weeks. The 12-week extension period was a period to evaluate the safety of this drug, and patients who were taking rosuvastatin single drug were switched to a combination drug with the same rosuvastatin dose. Of the 333 patients who completed the 8-week treatment period, 261 were enrolled in the extension period, of which 231 completed the extension period.
4) Toxicity test information
(1) Repeated dose toxicity
A repeated dose toxicity test was conducted in rats in which the test substance (rosuvastatin/ezetimibe) was orally administered for 13 weeks, and no new unknown toxicological changes were observed in each single ingredient.
(2) Reproductive and developmental toxicity
Although additional reproductive and developmental toxicity tests were not conducted for the development of combination drugs, the known reproductive and developmental toxicity for each single drug is as follows.
① Rosuvastatin: In pre- and post-natal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and reduced survival of the next generation. This effect was observed when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
② Ezetimibe: Reproductive toxicity was not observed in a reproductive toxicity test in which ezetimibe was orally administered to female and male rats up to the maximum dose of 1000 mg/kg/day (approximately 7 times the human exposure when administered at 10 mg per day based on AUC0-24hr of total ezetimibe).
(3) Carcinogenicity test
Although additional carcinogenicity tests were not conducted for the development of combination drugs, the known carcinogenicity tests for each single agent are as follows.
① Ezetimibe: A 104-week carcinogenicity test was conducted in rats in which ezetimibe was orally administered to male and female rats at a maximum dose of 1500 mg/kg/day and 500 mg/kg/day (approximately 20 times the human exposure when administered at 10 mg per day based on AUC0-24hr of total ezetimibe). A 104-week carcinogenicity study was also conducted in mice with ezetimibe orally administered up to a maximum dose of 500 mg/kg/day (more than 150 times the human exposure when administered at 10 mg per day, based on the AUC0-24hr of total ezetimibe). Tumor expression in rats and mice administered the drug did not increase statistically significantly.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets (10 tablets/Alu-Alu
7. Period of use
36 months from date of manufacture
- Active ingredient: Ezetimibe (micronized) (in-house specification) ---------- 10mg
Rosuvastatin Calcium (EP) ---------- 10.4mg (10mg as rosuvastatin)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Microcrystalline cellulose, butyl hydroxyanisole, magnesium stearate, Opadry white (03B28796), carnauba lead, croscarmellose sodium, hydroxypropyl cellulose
2. Efficacy/Effectiveness
Primary hypercholesterolemia
This drug is administered as an adjunct to diet to reduce elevated total cholesterol (total-C), LDL-C, apo B protein (Apo B), triglyceride (TG), and non-HDL-cholesterol and to increase HDL-cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia.
Many risk factors must be considered when administering lipid-modifying drugs to patients at increased risk of arteriosclerotic vascular disease due to hypercholesterolemia. Lipid-modifying drugs should be used in conjunction with appropriate diet (including restriction of saturated fat and cholesterol) and when response to diet and other non-pharmacological measures is inadequate.
Prior to administering this drug, other secondary causes of dyslipidemia (e.g., diabetes, hypothyroidism, obstructive liver disease, chronic renal failure, drugs that increase LDL-cholesterol and drugs that reduce HDL-cholesterol [progestin, anabolic steroid, and corticosteroid]) should be identified, and secondary causes should be treated if necessary.
Lipid testing should include total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides. If the triglyceride level is more than 400 mg/dL (more than 4.5 mmol/L), the LDL-cholesterol concentration must be measured by ultracentrifugation. If you are hospitalized for an acute coronary accident, lipids should be measured upon admission or within 24 hours after admission. This measurement can be used as a reference in starting LDL-lowering treatment before or upon discharge of the patient.
3. Usage/Dosage
This drug is administered once daily, regardless of meal.
Patients before or while taking this drug must continue to follow a standard cholesterol-lowering diet. The dosage of this drug should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goals, and patient response.
Primary hypercholesterolemia
The dosage range of this drug is 10/5mg to 10/20mg per day. The recommended initial dose is 10/5 mg per day. For patients who require greater LDL-cholesterol reduction, the dose can be adjusted. After starting this drug or titrating the dose, check the blood lipid level at intervals of 4 weeks or more and adjust the dose accordingly. The dose can be increased up to 10/20 mg per day.
If a patient is taking ezetimibe and rosuvastatin in combination, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.
4. Precautions for use
1. Warning
Rhabdomyolysis accompanied by acute renal failure secondary to myoglobinuria has been rarely reported with rosuvastatin and other drugs in the same class. Therefore, treatment with this drug should be temporarily withheld or discontinued in patients presenting with acute, severe myopathy or with risk factors that may cause renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, uncontrolled seizures) (see ‘5. General Precautions’).
2. Do not administer to the following patients
1) Patients with hypersensitivity to the main ingredient or components of this drug
2) Patients with active liver disease or patients with persistently high serum transaminase levels for unknown reasons (see ‘5. General precautions’)
3) Patients with muscle disease
4) Patients taking cyclosporine concurrently
5) Patients with severe renal failure (creatinine clearance (CLcr) <30mL/min)
6) Pregnant women, women who may be pregnant, and lactating women (see ‘7. Administration to pregnant and lactating women’)
7) Rosuvastatin at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
(1) Moderate renal impairment (creatinine clearance <60ml/min)
(2) Hypothyroidism
(3) If you have a history or family history of genetic muscle disease
(4) If there is a history of muscle toxicity from other statin drugs (HMG-CoA converting enzyme inhibitors) or fibrate drugs
(5) alcoholism
(6) Situations in which plasma concentrations may increase
(7) Asian patients
(8) Concurrent administration of fibrate-based drugs
8) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer with caution to the following patients:
1) Patients with a history of alcoholism or liver disease
2) Patients with moderate or severe liver function impairment: In patients with moderate or severe liver function impairment, administration of this drug is not recommended as the systemic exposure to rosuvastatin and ezetimibe may increase and unexpected effects may occur.
3) Patients with factors predisposing to myopathy/rhabdomyolysis, such as:
(1) History of impaired renal function or renal failure
(2) Hypothyroidism
(3) History or family history of genetic muscle disease
(4) History of muscle toxicity to statin drugs or fibrate drugs
(5) If you have a history of liver disease or consume a significant amount of alcohol
(6) Elderly over 70 years old with factors causing rhabdomyolysis
(7) Cases where blood drug concentration may increase
4) Patients taking concomitant fibrate drugs
5) Patients with severe muscle atony or ocular muscle atony (cases of recurrence when administered the same or different types of statin drugs have been reported).
6) Acute severe conditions suggestive of worsening myopathy or renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte disorders, uncontrolled epileptic seizures)
4. Adverse reactions
○ Information collected from ezetimibe/rosuvastatin combination drug
1) The safety of this drug was evaluated in a rosuvastatin-controlled clinical trial targeting 369 patients with primary high cholesterol. This clinical trial consists of an 8-week treatment period and a 12-week extension period. The 12-week extension period was conducted on 258 patients who completed the 8-week treatment period and whose LDL-C levels reached the treatment target according to their risk for cardiovascular disease.
(1) Adverse reactions collected during the 8-week treatment period
The most commonly reported adverse reactions during this period were nasopharyngitis (2.4%), arthralgia (1.4%), and headache (1.4%). Adverse reactions related to this drug were 2 cases of ALT elevation, 2 cases of AST elevation, 2 cases of muscle pain, 1 case of edema, 1 case of increase in blood bilirubin, 1 case of acneiform dermatitis, and 1 case of pruritus, all of which were mild or moderate.
<Table 1> Adverse reactions reported in more than 1% of patients during the 8-week treatment period
* Please refer to the attached manual for detailed information. *
(2) Adverse reactions collected during the 12-week extension period
The most commonly reported adverse reactions during this period were nasopharyngitis (5.04%), increased ALT (2.71%), increased AST (1.94%), dizziness (1.94%), upper respiratory tract infection (1.55%), and muscle pain (1.16%). All other adverse reaction incidence rates were less than 1%. As with the 8-week controlled clinical trial of rosuvastatin, no adverse reactions specific to this drug were observed.
2) Domestic post-marketing surveillance results following re-examination
For reexamination in Korea, six post-marketing surveys of ezetimibe/rosuvastatin combination drugs were conducted on a total of 10,317 people over a period of six years. Regardless of causal relationship, the occurrence rate of adverse events was 11.11% (71/639 people, 101 cases), 11.61% (529/4556 people, 790 cases), 15.85% (100/631 people, 156 cases), 11.73% (306/2,608 people, 412 cases), respectively, for each post-marketing surveillance. It was reported as 6.76% (85/1,258 people, 117 cases) and 6.88% (43/625 people, 59 cases). Among these, serious adverse drug reactions for which a causal relationship cannot be ruled out and unexpected adverse drug reactions for which a causal relationship cannot be ruled out were reported as shown in the table below.
* Table_Please refer to the attached manual for detailed information. *
* The number of serious adverse drug reactions and unexpected adverse drug reactions listed in the table above is a compilation of individual post-marketing surveillance results.
The information specified below is based on clinical trials and post-marketing experience with the individual ingredients rosuvastatin and ezetimibe.
○ Information collected from rosuvastatin
1) Reported adverse reactions were generally mild and transient. Less than 4% of patients in the rosuvastatin treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows:
Common (>1/100, <1/10);
Uncommon (>1/1,000, <1/100);
Rare (>1/10,000, <1/1,000);
Very rare (<1/10,000).
Not known (cannot be estimated from available data)
<Table 2> Adverse reactions occurring during rosuvastatin administration
* Please refer to the attached manual for detailed information. *
As with other statin drugs, adverse reactions tended to increase as the dose increased.
2) Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered rosuvastatin, but the frequency of occurrence was low.
3) Effects on the musculoskeletal system: Effects on the musculoskeletal system with or without acute renal failure (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) have been reported in patients treated with all doses of rosuvastatin (especially doses above 20 mg). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
4) Effects on the liver: As with other statin drugs, transaminase levels increased in a dose-dependent manner in a small number of patients receiving rosuvastatin. In most cases, it was mild, asymptomatic, and transient.
5) Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with increased eosinophils and systemic symptoms (DRESS) (frequency unknown)
- Musculoskeletal system: very rare, arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
Post-marketing cognitive impairment has been rarely reported in association with statin drug use. (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks). The induction or worsening of severe muscle atony or ocular muscle atony has been reported with the administration of statin drugs.
6) Domestic post-marketing survey results
As a result of a use result survey conducted on 3,081 people over 6 years for re-examination in Korea, the incidence of adverse events regardless of causal relationship was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) respectively. Of these, 2.92% (90 people, 106 cases) of adverse drug reactions for which a causal relationship with rosuvastatin could not be ruled out.
The most reported adverse drug reactions were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not occur before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% each (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% each (2 patients, 2 cases), syncope, and Systemic pain, muscle spasms, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased blood creatinine were reported as serious and unexpected adverse drug reactions.
7) Pediatric patients aged 10 to 17 years
In a 52-week clinical trial conducted on pediatric patients aged 10 to 17 years, elevated creatinine kinase levels exceeding 10 times the upper limit of normal range (10 x ULN) after exercise and increased physical activity were observed more frequently than in adult patients. In other respects, the safety profile of pediatric patients was similar to that of adults.
○ Information collected from ezetimibe
The safety of ezetimibe was evaluated in more than 4,700 patients in clinical trials. As a result of clinical trials on ezetimibe (administered alone or in combination with an HMG-CoA reductase inhibitor), ezetimibe was generally well tolerated. The total incidence of adverse reactions reported with ezetimibe was similar to the incidence of adverse reactions reported with placebo, and the rate of discontinuation of medication due to adverse reactions was also similar to that of placebo.
1) Single administration
In placebo-controlled clinical trials, adverse reactions were reported in more than 2% of patients administered ezetimibe, regardless of causality assessment, and adverse reactions reported at a higher rate than the incidence in the placebo group are shown in <Table 3>.
<Table 3*> Clinical adverse reactions reported in more than 2% of patients treated with ezetimibe, regardless of causality assessment, and reported at a higher rate than the rate in the placebo group
* Please refer to the attached manual for detailed information. *
The occurrence rates of other adverse reactions that occurred at a lower frequency than the above adverse reactions were similar between the ezetimibe group and the placebo group (see Table 4).
2) Concurrent administration with HMG-CoA reductase inhibitor
The safety of ezetimibe was evaluated in more than 2,000 patients in a combination clinical trial.
Adverse reactions when ezetimibe and HMG-CoA reductase inhibitors were administered together were generally similar to those when HMG-CoA reductase inhibitors were administered alone. However, compared to patients receiving HMG-CoA reductase inhibitors alone, patients receiving ezetimibe and HMG-CoA reductase inhibitors together had a slightly higher incidence of elevated aminotransferase levels.
In four placebo-controlled clinical trials in which ezetimibe was administered alone or simultaneously with various HMG-CoA reductase inhibitors, adverse reactions that were reported in more than 2% of cases regardless of causality assessment and that were reported at a higher rate than the placebo group are shown in <Table 4>.
<Table 4*> Clinical adverse reactions reported in more than 2% of patients regardless of causality assessment in clinical trials of ezetimibe/statin combination administration and at a higher rate than the placebo group
* Please refer to the attached manual for detailed information. *
3) Concurrent administration with fenofibrate
A multicenter, double-blind, placebo-controlled clinical trial was conducted on 625 patients with mixed dyslipidemia for up to 12 weeks and 576 patients with mixed dyslipidemia for up to 1 year. This study was not designed to compare rare adverse reactions between treatment groups. The incidence (95% CI) of clinically important elevations (more than 3 times the upper limit of normal, persistent) of serum transaminases was 4.5% (1.9, 8.8) in the fenofibrate monotherapy group and 2.7% (1.2, 5.4) in the ezetimibe and fenofibrate combination group, when adjusting for dose exposure. The incidence of cholecystectomy was 0.6% (0.0, 3.1) in the fenofibrate-only group and 1.7% (0.6, 4.0) in the ezetimibe and fenofibrate combination group. In each administration group of this test, there was no case where creatine phosphokinase (CPK) increased more than 10 times the upper limit of normal.
4) Commonly reported adverse reactions related to the drug in the ezetimibe alone group (n=1691), the ezetimibe and statin drug combination group (n=1675), or the ezetimibe and fenofibrate combination treatment group (n=185) are as follows (≥1/100, <1/10).
․Ezetimibe single-administration group: Headache, abdominal pain, diarrhea
․Ezetimibe and statin drug combination group: headache, fatigue, abdominal pain, constipation, diarrhea, flatulence, nausea, increased AST, increased ALT, muscle pain.
․Ezetimibe and fenofibrate combination group: abdominal pain
5) Post-marketing adverse reactions
The following adverse reactions were reported post-marketing regardless of causality assessment.
Hypersensitivity reactions including anaphylaxis, urticaria, rash and angioedema, erythema multiforme, arthralgia, myalgia, increased creatine phosphokinase level, myopathy/rhabdomyolysis (see section ‘5. General precautions’), increased liver aminotransferase level, hepatitis, abdominal pain, thrombocytopenia, nausea, pancreatitis, dizziness, paresthesia, depression, headache, cholelithiasis, cholecystitis.
6) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,536 patients over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 7.27% (257/3,536, 422 cases) regardless of causal relationship. The most common adverse event (more than 1.0%) was fatigue at 1.05% (37 people/3,536 people, 37 cases). The adverse drug reaction rate, which is an adverse event in which a causal relationship with ezetimibe cannot be ruled out, was 1.95% (69 people/3,536 people, 108 cases). Increased ALT and AST were the most common at 0.28% (10 people/3,536 people, 10 cases), followed by diarrhea at 0.17% (6 people/3,536 people, 6 cases), indigestion and dizziness at 0.14% (5 people/3,536 people, 5 cases) each, and nausea at 0.11% (4 people/3,536 people, 5 cases). 4 cases), and other adverse drug reactions reported in less than 0.1% are classified by institution as follows.
- Whole body: fatigue, chest pain, chest discomfort, edema, asthenia, generalized edema
- Nervous system: headache, diabetic neuropathy, tremor
- Digestive system: epigastric pain, vomiting, abdominal pain, gastritis, constipation, dry mouth, solar plexus discomfort, belching, gastrointestinal disorders, gastroesophageal reflux disease, tongue disease
- Cardiovascular system: palpitations, congestive heart failure, myocardial ischemia, flushing
- Respiratory system: cough, phlegm, runny nose
- Musculoskeletal system: limb pain, joint pain
- Metabolism and nutrition: diabetes, hypoglycemia
- Blood system: anemia, splenomegaly
- Skin: hives, hyperhidrosis, rash, itching
- Infection: Upper respiratory infection
- Eyes: Conjunctival redness
- Urinary system: renal failure (kidney disease)
- Hepatobiliary system: liver dysfunction
- Clinical tests: increased blood creatinine, increased blood pressure, increased blood urea, increased CPK, abnormal liver function test
5. General precautions
1) Myopathy/Rhabdomyolysis
For patients with factors predisposing to myopathy/rhabdomyolysis (see section ‘3. Administer with caution to the following patients’), CPK levels should be measured before starting administration and administered with caution. In these patients, the risks of treatment should be considered along with the benefits, and clinical monitoring is recommended.
CPK is not measured after strenuous exercise or when there are other potential factors that may cause CPK elevation, as it is difficult to interpret CPK levels. If the CPK level significantly increases from baseline to more than 5 times the upper limit of normal, it should be measured again after 5 to 7 days to confirm the result.
If CPK levels are significantly increased beyond 5 times the upper limit of normal from baseline after 5 to 7 days, treatment with this drug should not be initiated.
When starting treatment with this drug, patients should be informed of the risk of myopathy, and if muscle pain, cramps, or muscle weakness accompanied by malaise or fever occur while taking this drug, patients should be instructed to immediately report this to their doctor. Additionally, if these symptoms occur, CPK levels should be measured, and if CPK levels increase significantly (more than 5 times the upper limit of normal), administration of this drug should be discontinued. Even if the CPK level is less than 5 times the upper limit of normal, the drug should be discontinued if muscle symptoms are severe and cause daily discomfort. If symptoms improve and CPK levels return to normal and this drug is re-administered or other statin-containing preparations are administered, administer at the lowest dose while closely monitoring the patient.
○ Rosuvastatin
As with other statins, effects on skeletal muscle, such as myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving rosuvastatin. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statin drugs, including rosuvastatin. Immune-mediated myopathy is clinically characterized by proximal muscle weakness and increased CPK in the blood, and the symptoms persist even after discontinuation of administration.
In clinical trials, there was no evidence of increased effects on skeletal muscle in the small number of patients receiving rosuvastatin in combination with other drugs. However, in the case of other statin drugs, the frequency of myositis and myopathy increased in patients who were also receiving fibric acid derivatives (including gemfibrozil), cyclosporin, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when combined with statin drugs. Therefore, combined use of rosuvastatin and gemfibrozil is not recommended. When rosuvastatin is coadministered with fibrates or niacin, the benefits and risks must be carefully evaluated. A dose of 40 milligrams of rosuvastatin is contraindicated when coadministered with fibrate-based drugs.
○ Ezetimibe
The risk of musculoskeletal toxicity increases when there are factors such as concurrent use with high-dose statin drugs, elderly patients (over 65 years of age), hypothyroidism, renal impairment, type of statin drug administered, and concurrent use with other drugs.
Myopathy and rhabdomyolysis have been reported with ezetimibe after marketing. Most patients who developed rhabdomyolysis were taking statins before receiving ezetimibe. However, rhabdomyolysis has been reported when ezetimibe is administered alone, and rhabdomyolysis has also been reported when ezetimibe is coadministered with drugs that increase the risk of rhabdomyolysis, such as fibric acid derivatives.
If myopathy is diagnosed or suspected when coadministering ezetimibe and fenofibrate, administration of ezetimibe and fenofibrate should be discontinued immediately. Cases where CPK levels rise to more than 10 times the upper limit of normal along with muscle symptoms can be considered myopathy.
2) Liver enzymes
Liver enzyme tests should be performed before starting treatment with this drug, and liver function tests should be repeated in patients who demonstrate clinical signs or symptoms of liver damage. Patients with elevated transaminases should be monitored until symptoms improve. If transaminases continue to increase more than 3 times the upper normal limit, it is recommended to reduce the dose or discontinue the drug.
In post-marketing studies in patients taking statins, including rosuvastatin, rare cases of fatal and non-fatal liver failure have been reported.
If severe liver damage and/or hyperbilirubinemia or jaundice occurs along with clinical symptoms during treatment with this drug, treatment with this drug should be discontinued immediately. If no other etiology is identified, do not re-administer this drug.
Caution should be exercised when administering this drug to patients who have overdosed on alcohol and/or have a history of liver disease. This drug should not be administered to patients with active liver disease or persistent elevations in serum transaminases of unknown cause. (Refer to ‘2. Do not administer to the following patients’)
○ Ezetimibe
In controlled clinical trials, the incidence of persistent elevations in liver aminotransferase levels (more than three times the upper limit of normal) was similar in the ezetimibe group (0.5%) and the placebo group (0.3%).
In a controlled clinical trial on the combined administration of ezetimibe and statins, the incidence of consecutive elevations in liver aminotransferase levels (more than three times the upper limit of normal) was 0.6% in the group administered with ezetimibe and statins. These aminotransferase elevations generally did not cause symptoms, were not related to cholestasis, and returned to baseline levels after discontinuation or continued administration.
3) Endocrine system function
Increases in HbA1c and fasting blood sugar levels have been reported in patients taking statins, including rosuvastatin. However, the benefit of reducing vascular risk from statin administration outweighs the risk of hyperglycemia.
4) Interstitial lung disease
Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Symptoms that develop may include difficulty breathing, non-productive cough and general deterioration of health (fatigue, weight loss and fever). If a patient is suspected of having interstitial lung disease, treatment with statin drugs should be discontinued.
5) Diabetes
There is some evidence that statins may cause hyperglycemia, which may require appropriate diabetes treatment in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statin drugs exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar level 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo both clinical and laboratory monitoring according to treatment guidelines.
6) Concurrent administration with other drugs
(1) Anticoagulants: When adding this drug to patients taking warfarin, other coumarin anticoagulants, or fluinedione, the INR must be appropriately monitored. Additionally, when administering this drug to a patient taking a coumarin-based anticoagulant, the prothrombin time should be measured before administration and should be measured frequently enough in the early stages of treatment to confirm that the prothrombin time does not change significantly. Once a stable prothrombin time is established, it can be monitored periodically. If the dose of this drug is changed or treatment is discontinued, the same process as above must be repeated.
(2) Fibrate-based drugs: Fibrate-based drugs can cause cholelithiasis by increasing cholesterol excretion into bile. If cholelithiasis is suspected in patients taking this drug and fibrates in combination, gallbladder investigation should be performed and alternative lipid-lowering therapy should be considered.
(3) Bile acid binding resin: This drug should be administered 2 hours before or 4 hours after administration of bile acid binding resin.
(4) Fusidic acid: In post-marketing experience, muscle-related adverse reactions, including rhabdomyolysis, were reported when rosuvastatin and fusidic acid were used together, so the combined use of rosuvastatin and fusidic acid is not recommended.
(5) Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP. Caution should be exercised when using this drug together with an inhibitor of this transporter protein, as the blood concentration of this drug may increase, increasing the risk of myopathy (see section 6. Interactions).
7) Genetic polymorphism: SLCO1B1(OATP1B1) c compared to SLCO1B1 c.521TT and ABCG2 c.421CC. The genotype of 521CC or ABCG2 (BCRP) c.421AA has been reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of this drug according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
8) Women of childbearing potential
Women of childbearing potential should use appropriate contraception while taking this drug.
9) Effects on driving and operating machines: There have been no studies on the effects on driving and operating machines, but it should be considered that dizziness may occur in patients taking this drug.
10) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS), eosinophilia, and drug reaction syndrome with systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be counseled and closely monitored for symptoms and signs of severe skin reactions. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
11) Severe muscle asthenia and ocular muscle atony: Rarely, statin drugs may cause or worsen severe muscle asthenia or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.
6. Interaction
No clinically significant pharmacokinetic interactions were observed when co-administered with rosuvastatin, the main ingredient of this drug, and ezetimibe.
Studies on drug interactions between other drugs and rosuvastatin/ezetimibe combination drugs have not been conducted, but studies on individual drugs rosuvastatin and ezetimibe have been conducted as follows.
○ Rosuvastatin
1) How other drugs affect rosuvastatin
In vitro and in vivo studies have shown that rosuvastatin does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP, and when inhibitors of these transporter proteins are used together with rosuvastatin, the blood concentration of rosuvastatin increases, which may increase the risk of myopathy (see Table 5 below).
Table 5: Effect of other drugs on rosuvastatin exposure (AUC) (based on published clinical results)
* Please refer to the attached manual for detailed information. *
Effects of other drugs
(1) Antacid: When rosuvastatin was co-administered with an antacid containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by about 50%. However, this effect was alleviated when antacids were administered 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.
(2) Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
(3) Ticagrelor: Ticagrelor may affect the excretion of rosuvastatin through the kidneys, increasing the risk of rosuvastatin accumulation. In some cases, coadministration of ticagrelor and rosuvastatin resulted in decreased renal function, increased CPK levels, and rhabdomyolysis.
2) Effect of rosuvastatin on other drugs
(1) Warfarin: When used in combination with rosuvastatin, warfarin has no significant effect on pharmacokinetics. However, like other statin drugs, coadministration of rosuvastatin and warfarin may increase the INR compared to administration of warfarin alone. INR monitoring is recommended when starting, stopping, or adjusting the dose of rosuvastatin in patients receiving vitamin K antagonists (e.g., warfarin).
(2) Cyclosporine: Co-administration of rosuvastatin and cyclosporine does not affect the blood concentration of cyclosporine.
(3) Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, so the risk of myopathy increases when administered in combination with statin drugs. When co-administering fibrate-type drugs, administration of 40 mg of rosuvastatin is contraindicated, and 5 mg should be administered as the initial dose.
(4) Oral contraceptives: When administered together with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data for patients taking rosuvastatin and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
(5) Effect on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
○ Ezetimibe
1) Cholestyramine: When ezetimibe and cholestyramine were administered together, the average AUC of total ezetimibe decreased by about 55%. Due to this interaction, the combined effect on lowering LDL-C expected from the combined administration of cholestyramine and ezetimibe may be reduced.
2) Fibrate-based drugs: In clinical trials, the safety and effectiveness of combined administration of ezetimibe and fenofibrate were evaluated. Coadministration of ezetimibe with other fibrates has not been studied. Fibrates can cause gallstones by increasing cholesterol excretion into bile. Ezetimibe increased gallbladder bile cholesterol in preclinical studies in dogs. Although the relevance of these preclinical findings to humans is unknown, coadministration of ezetimibe and fibrates (except fenofibrate) is not recommended until the results of studies in patients are available.
(1) Gemfibrozil: In a pharmacokinetic study, the total ezetimibe concentration increased by about 1.7 times with the combined administration of ezetimibe and gemfibrozil, but this was not clinically significant. There is no relevant clinical data yet.
(2) Fenofibrate: If cholelithiasis is suspected in a patient taking ezetimibe and fenofibrate together, the gallbladder should be examined and other lipid-lowering treatment should be considered. In a pharmacokinetic test, combined administration of ezetimibe and fenofibrate increased the total ezetimibe concentration by approximately 1.5 times, but this was not clinically significant.
3) Statin drugs: No clinically significant pharmacokinetic interactions were observed when coadministering ezetimibe with atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, and rosuvastatin.
4) Cyclosporine: Caution should be exercised when co-administering ezetimibe to patients taking cyclosporine. If ezetimibe and cyclosporine are coadministered, the concentration of cyclosporine should be monitored. When ezetimibe was co-administered with a stable dose of cyclosporine (75-150 mg twice daily) to eight kidney transplant patients with mild renal impairment or normal renal function (creatinine clearance > 50 mL/min), the average AUC and C max of total ezetimibe were 3.4 times each (range) compared to healthy historical controls (n=17). It increased to 2.3 to 7.9 times) and 3.9 times (range 3.0 to 4.4 times). In another clinical study, when several drugs, including cyclosporine, were administered to one patient with severe renal impairment (creatinine clearance = 13.2 mL/min/1.73 m2) who had received a kidney transplant, the total ezetimibe exposure increased 12-fold. In a two-period crossover study in 12 healthy volunteers, when ezetimibe 20 mg once daily for 8 days and cyclosporine 100 mg as a single dose on day 7 were administered as a single dose, the AUC of cyclosporine increased by an average of 15% compared to the control group when cyclosporine 100 mg was administered alone (range 10% decrease to 51% increase).
5) Anticoagulants: When coadministering ezetimibe with warfarin, other coumarin anticoagulants, or fluinedione, the prothrombin time (International Normalized Ratio, INR) must be appropriately monitored. In a clinical study involving 12 healthy adult men, there was no significant effect on the bioavailability and prothrombin time of warfarin due to the co-administration of warfarin and ezetimibe (10 mg per day). However, after marketing, it was reported that INR increased in patients who received ezetimibe in combination with warfarin or fluindione. Most of these patients were also taking other medications.
7. Administration to pregnant and lactating women
1) Arteriosclerosis is a chronic disease, and discontinuation of lipid-lowering medication during pregnancy does not affect the long-term treatment results of primary hypercholesterolemia. Additionally, cholesterol and other products of the cholesterol biosynthetic pathway are essential components for fetal development, such as steroids and cell membrane synthesis.
HMG-CoA reductase inhibitors, including rosuvastatin, may reduce cholesterol synthesis and other products of the cholesterol biosynthetic pathway, so this drug should not be administered to pregnant or lactating women.
Since the safety of this drug in pregnant women has not been established, administration should be discontinued immediately if pregnancy is confirmed, and the patient should be informed of the potential risk to the fetus. For women of childbearing potential who have little chance of becoming pregnant, administer the drug only after being informed of the potential risk to the fetus and the lack of clinical benefit from continuing administration during pregnancy.
2) Since it has not been confirmed whether the components of this drug are secreted into breast milk, this drug should not be administered to nursing mothers unless the potential benefit of this drug outweighs the potential risk to the infant.
○ Rosuvastatin
The safety of rosuvastatin in pregnant and lactating women has not been established and should not be used during pregnancy or lactation.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using rosuvastatin, you should stop taking it immediately. Rosuvastatin is passed into rat breast milk. There are no data on transfer to breast milk in humans.
○Ezetimibe
1) There is no clinical data on the administration of ezetimibe to pregnant women. Ezetimibe should be used in pregnant women only when the potential benefits outweigh the potential risks to the infant.
2) No embryonic lethal effect was observed at the test doses (250, 500, 1000 mg/kg/day) in oral embryo/fetal development tests on rats and rabbits in the organogenesis period. In rats administered ezetimibe at 1000 mg/kg/day (10 times the human exposure at 10 mg/day based on the AUC0-24hr of total ezetimibe), an increased incidence of common fetal skeletal abnormalities (rib extraplasia, central cervical ossification, and rib shortening) was observed. Rib addition was observed in rabbits administered ezetimibe at 1000 mg/kg/day (150 times the human exposure at 10 mg/day based on AUC0-24hr of total ezetimibe). Ezetimibe crossed the placenta when repeatedly administered to pregnant rats and rabbits.
3) All HMG-CoA reductase inhibitors and fenofibrate are prohibited for administration to pregnant and lactating women. When administering ezetimibe together with an HMG-CoA reductase inhibitor or fenofibrate to women of childbearing potential, refer to the product instructions for the relevant HMG-CoA reductase inhibitor or fenofibrate.
4) In a repeated administration test in which ezetimibe and HMG-CoA reductase inhibitors (statin drugs) were co-administered to rats and rabbits in the organogenesis period, the degree of exposure to ezetimibe and HMG-CoA reductase inhibitors was high. Abnormalities in reproductive function were observed at lower doses during combined administration compared to single administration.
5) In animal experiments (rats), ezetimibe was secreted into milk. In experiments in rats, total ezetimibe exposure in lactating pups was half that observed in maternal plasma. It is not known whether ezetimibe is excreted in human breast milk. Therefore, ezetimibe should not be administered to nursing mothers unless the potential benefits of ezetimibe outweigh the potential risks to the infant.
8. Administration to children
This drug is not recommended for use in children because its safety and effectiveness have not been established.
○ Rosuvastatin
In pediatric patients aged 10 to 17 years taking rosuvastatin, evaluation of secondary sexual characteristics, linear growth (height), weight, and body mass index (BMI) by Tanner staging is limited to 1 year.
○ Ezetimibe
To evaluate the safety and effectiveness of ezetimibe, a clinical trial was conducted for 12 weeks on pediatric patients (6-10 years old) with heterozygous familial and non-familial hypercholesterolemia. The adverse reaction profile when ezetimibe was administered to pediatric patients and the adverse reaction profile when administered to adult patients were similar. This clinical trial found no effects on development or sexual maturation in children. However, there are no studies in which ezetimibe was administered to pediatric patients for more than 12 weeks.
9. Administration to elderly people
Old age (over 65 years old) is one of the factors that predisposes to myopathy, so caution should be exercised when administering this drug to elderly people. No dosage adjustment of this drug is necessary in elderly people.
10. Administration to patients with hepatic impairment
Do not administer this medicine to patients with active liver disease or unexplained, persistently elevated hepatic aminotransferase levels. See “2. Contraindications” and “5. General Precautions.”
11. Administration to patients with renal impairment
A history of renal impairment may be a risk factor for developing rhabdomyolysis. These patients may benefit from close monitoring of skeletal muscle effects (see ‘5. General precautions’).
○Ezetimibe
After administering ezetimibe 10mg once daily to patients with severe renal impairment (n=8, creatinine clearance ≤ 30ml/min/1.73㎡), the average AUC of total ezetimibe increased by about 1.5 times compared to healthy subjects (n=9). These results are not clinically significant, and no dose adjustment is necessary for patients with renal impairment.
12. Treatment in case of overdose
There is no specific treatment recommended for overdose of this drug. In case of overdose of this drug, symptomatic treatment and appropriate supportive care should be provided. Additionally, liver function tests and serum CPK levels should be monitored.
○ Ezetimibe
1) There have been several reports of overdose with ezetimibe. Most of them were not accompanied by adverse reactions, and the adverse reactions reported were not severe. In case of overdose, provide general symptomatic and supportive care.
2) In clinical trials, tolerability was generally excellent when 50 mg of ezetimibe per day was administered to 15 healthy subjects for up to 14 days, or when 40 mg of ezetimibe per day was administered to 18 patients with primary dyslipidemia for up to 56 days.
13. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
14. Information for experts
1) Pharmacological action
(1) Rosuvastatin is an HMG-CoA reductase inhibitor and inhibits the synthesis of mevalonate, a precursor of cholesterol.
(2) Ezetimibe selectively inhibits the intestinal absorption of cholesterol and phytosterols.
2) Pharmacokinetic information
(1) One biopharmaceutical study compared the bioavailability of this fixed-dose combination with that of the individual products taken together. In a 2 × 2 crossover study, 41 healthy adults received a single fasting dose of rosuvastatin 10 mg and ezetimibe 10 mg, either as the combination or as separate products (test: one 10/10 mg tablet of this product; reference: one Crestor 10 mg tablet and one Ezetrol tablet). Pharmacokinetic parameters were compared using plasma rosuvastatin and ezetimibe concentrations. The 90% confidence intervals for the differences in the means of the log-transformed AUCt and Cmax values were all within log 0.8 to log 1.25, meeting the bioequivalence criteria.
(2) One comparative pharmacokinetic study was conducted to evaluate the pharmacokinetic drug interaction between rosuvastatin and ezetimibe. A total of 56 healthy adults participated and took 20 mg of rosuvastatin and 10 mg of ezetimibe alone or in combination for 7 days (2 treatment groups, 2 × 2 crossover trial each). The 90% confidence interval of the log-transformed mean difference of AUCτ,ss and Cmax,ss during combined administration compared to single administration is 1.037 (0.977 ~ 1.101) and 1.037 (0.945 ~ 1.137) for rosuvastatin, respectively, and 1.211 (1.094 ~ 1.341) for free ezetimibe, respectively. and 1.130 (0.994 ~ 1.285), and the total ezetimibe including active metabolites were 1.130 (1.022 ~ 1.249) and 1.069 (0.976 ~ 1.171), respectively. No clinically significant pharmacokinetic interaction was observed when the two components were administered together.
(3) Although not a test conducted with this drug, rosuvastatin increased the median AUC and Cmax approximately two-fold in Asians (Japan, China, Philippines, Vietnam, Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
3) Clinical trial information
One multicenter, randomized, double-blind, parallel, factorial design trial was conducted with 369 patients (safety set) with primary hypercholesterolemia. This trial consisted of an 8-week treatment phase and a 12-week extension phase. In this trial, patients underwent therapeutic lifestyle correction for more than 4 weeks before randomization, and then a fasting lipid test was performed. Finally, eligible subjects were randomly assigned to the test group (10/20 mg, 10/10 mg, 10/5 mg of this drug) or the control group (20 mg, 10 mg, 5 mg of rosuvastatin).
After an 8-week treatment period, a superiority test was conducted at a significance level of 5% between the overall rosuvastatin/ezetimibe combination group compared to the overall rosuvastatin single agent group at all doses. As a result, the rosuvastatin/ezetimibe combination group showed a statistically superior LDL-C lowering effect compared to the rosuvastatin single agent group (p-value <0.0001).
As a result of sequentially testing the superiority of the rosuvastatin/ezetimibe combination group over the rosuvastatin single agent group at rosuvastatin doses of 5 mg, 10 mg, and 20 mg, the rosuvastatin/ezetimibe combination group showed a statistically superior LDL-C lowering effect compared to the rosuvastatin single agent group at all doses (p-value<0.0001).
* Please refer to the attached manual for detailed information. *
After completing the treatment period, only patients whose LDL-C level reached the treatment goal according to NCEP ATP III took this drug for an additional 12 weeks. The 12-week extension period was a period to evaluate the safety of this drug, and patients who were taking rosuvastatin single drug were switched to a combination drug with the same rosuvastatin dose. Of the 333 patients who completed the 8-week treatment period, 261 were enrolled in the extension period, of which 231 completed the extension period.
4) Toxicity test information
(1) Repeated dose toxicity
A repeated dose toxicity test was conducted in rats in which the test substance (rosuvastatin/ezetimibe) was orally administered for 13 weeks, and no new unknown toxicological changes were observed in each single ingredient.
(2) Reproductive and developmental toxicity
Although additional reproductive and developmental toxicity tests were not conducted for the development of combination drugs, the known reproductive and developmental toxicity for each single drug is as follows.
① Rosuvastatin: In pre- and post-natal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and reduced survival of the next generation. This effect was observed when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
② Ezetimibe: Reproductive toxicity was not observed in a reproductive toxicity test in which ezetimibe was orally administered to female and male rats up to the maximum dose of 1000 mg/kg/day (approximately 7 times the human exposure when administered at 10 mg per day based on AUC0-24hr of total ezetimibe).
(3) Carcinogenicity test
Although additional carcinogenicity tests were not conducted for the development of combination drugs, the known carcinogenicity tests for each single agent are as follows.
① Ezetimibe: A 104-week carcinogenicity test was conducted in rats in which ezetimibe was orally administered to male and female rats at a maximum dose of 1500 mg/kg/day and 500 mg/kg/day (approximately 20 times the human exposure when administered at 10 mg per day based on AUC0-24hr of total ezetimibe). A 104-week carcinogenicity study was also conducted in mice with ezetimibe orally administered up to a maximum dose of 500 mg/kg/day (more than 150 times the human exposure when administered at 10 mg per day, based on the AUC0-24hr of total ezetimibe). Tumor expression in rats and mice administered the drug did not increase statistically significantly.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets (10 tablets/Alu-Alu
7. Period of use
36 months from date of manufacture
Product Updates
Total 4items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 4 | Duorovan Tab. 10/10 mg | Precautions for use | 2024.04.23 | PDFDuoroban Tablet 10│10mg_Permission change order (draft) (precautions for use).pdf |
| 3 | Duorovan Tab. 10/10 mg | Precautions for use | 2023.04.06 | PDF0296_201601223_Precautions for use_Duoroban tablet 10/10mg (including change comparison table).pdf |
| 2 | Duorovan Tab. 10/10 mg | Duoroban Tablet 10/10 mg (Precautions for use... | 2022.10.21 | PDF0056_201601223_Precautions for use_Duoroban tablet 10_10mg (tablet).pdf |
| 1 | Duorovan Tab. 10/10 mg | Precautions for use | 2022.01.25 | PDFDuoroban Tablet 10_10mg change plan (final).pdf |